Sales over science, profit over people, greed over need
Butterflies waft across a beautiful field of spring flowers. A delightful young family bicycles joyously down a country lane. A couple on a park bench leans sensually into each other. A 40-something woman's face radiates with both perfect beauty and internal happiness. "All's right with the world," is the message... as long as you've taken your dosages of Lunesta, Celebrex, Cialis, and Botox.
Welcome to medicated America, where the fix for every problem--from incontinence to erectile dysfunction, stiff joints to mood swings, weight gain to wrinkles-- is just a prescription away. Thus the beautiful images, stirring music, attractive actors, and soothing words in the omnipresent, multibillion-dollar kaleidoscope of drug advertising by Pfizer, Merck, Eli Lilly, Johnson & Johnson, and other giants of Big Pharma -- all pitching their particular brand-name nostrum directly at us hoi polloi (the industry spends a fourth of its income on ads and other promotions, nearly double its expenditures on research and development). The corporate come-ons typically conclude with a phrase that has achieved cliche status in America's vernacular: "Ask your doctor if 'Suprema Wundercure' is right for you."
The better question, though, is one that cartoonist Dan Piraro expressed in one of his "Bizzaro" panels: "Ask your doctor if playing into the hands of the pharmaceutical industry is right for you."
One would assume that in a rich, medically advanced, health-conscious nation like ours, dicey decisions about whether to allow a particular pharmaceutical product into our bodies would be among the most rational we make -- as determined by (1) the best science available, (2) the strict moral duty of medical purveyors to "First, do no harm," (3) good government regulation, and (4) the profession's fear of public reproach and legal punishment. One would, however, be wrong on all counts:
- Science has been supplanted by rank hucksterism
- The strictest "moral duty" of corporate executives has been reduced to maximizing profits
- A "good" regulation is one that's good for profit seekers
- Public reproach is just a momentary embarrassment to be covered over by corporate image makers
- Legal "punishment" never includes jail time, but only a fine that's easily absorbed as a necessary cost of doing business by these immensely profitable entities.
In the past three decades, America's health-care system has radically metamorphosed from a public service network (largely run by independent physicians and nonprofit hospitals) into a corporate profit machine -- one that Dr. Arnold Relman, the renowned former editor of the New England Journal of Medicine, calls the Medical-Industrial Complex. Drugmakers have been among the most ambitious, in-your-face pushers of this transmutation of medicine into just another commodity to be sold by hook or crook. In this system, the concept of "care" has been reduced to "caveat emptor," with the shareholders' interest in monetary gain overriding all other interests.The DTC Contagion
A fast-moving, systemic epidemic called DTC has swept across America, endangering public health, jacking up our costs, and weakening the curative connection between health professionals and patients. DTC stands for "Direct-to-Consumer" drug advertising. It's a plague of marketing, empowering profiteering corporations to short-circuit the judgment of doctors by using all of the tricks of Madison Avenue (including lies) to convince viewers and readers that (first) they're suffering from a particular malady, (second) the advertiser's brand-name medicine is the very best cure, and (finally) they must go to their doctors pronto to insist on getting a prescription for that specific drug. The essence of this marketing scheme is to turn consumers into sales representatives for drug peddlers. Brilliant.
Prescribing medicine through the television, radio, print, and internet ads of corporations (whose sole motive is to sell more pills) is so crass, so awash in conflicts of interest, and so inherently dangerous that only two countries have ever legalized it: New Zealand in 1981 and the USA in 1997.
In our country, the corporate-friendly government of Ronald Reagan first okayed DTC drug ads in 1985, but his Food and Drug Administration ruled that pages-long consumer warnings about health risks had to be included, so there were few takers. Then came Bill Clinton's corporate-friendly government, which issued a revised FDA rule in 1997 allowing drugmakers to dodge the full disclosure provision -- as long as their ads met an "adequate" standard for informing consumers about risks.
Such squishy words (slipped into regulations by industry lobbyists) are a corporate wet dream. Thanks to the adequacy loophole, fluffy-puffy, no-worries prescription drug ads quickly mushroomed. In 1997, spending on DTC ads was only $220 million; by 2002, it was $2.8 billion; and it has kept a steady pace of roughly $3 billion a year ever since.
Corporations don't spend that kind of money to dramatize the severity of their products' nasty side effects. As two ad execs giddily put it in a 1998 report to the industry, "The ultimate goal of DTC advertising is to stimulate consumers to ask their doctors about the advertised drug and then, hopefully, get the prescription." Obviously, to "get the prescription," corporate ads don't stress such unpleasant outcomes as these (taken from the small print of full-page ads for just a half dozen heavily advertised drugs): very high fevers, confusion, uncontrollable bowel movements, trouble swallowing, lower sperm count, prostate cancer, loss of vision, suicidal thoughts ... and, of course, death.
Side effects do have to be addressed, but not conspicuously -- for example, it's "adequate" for an off-camera announcer to buzz through them with a muted, fast-paced delivery (usually while cartoon butterflies flutter playfully on-screen to distract viewer attention). It's a disgusting, dishonorable way to generate sales -- but it works. In 2008, the House Commerce Committee found that every $1,000 spent on drug ads produces 24 new patients, and a 2003 research report found that prescription rates for drugs promoted with DTC ads were nearly seven times greater than those without such promos. Ethics aside, these consumer hustles have proven to be profit bonanzas:
- From 2000 through 2004, Merck & Co. poured more than $500 million into adverts promoting Vioxx, turning the pain pill into one of the "Top 100 Megabrands" listed by Advertising Age.
The drug was meant for the relatively few people who can't stomach
aspirin, but the PR push touted it to all arthritis patients, a much
larger marketing pool. The campaign promised "everyday victories" over
pain and immobility, featuring former Olympic skating champ Dorothy
Hamill spinning effortlessly (and pain-free) on the ice. Merck's ads
sold some 20 million Vioxx prescriptions, including to people who paid
the ultimate price for buying the hype -- a 2005 research report in The Lancet,
the prestigious British medical journal, attributed as many as 140,000
sudden cardiac "events" in America to the use of Vioxx. In September of
2004, Merck took the pill off the market over "safety concerns." As an
expert pharmacy consultant told Forbes magazine
in 2006, "Vioxx wasn't a bad drug for everyone, it was a bad drug for
certain patients. Unfortunately, people saw the ads and started
demanding the drug from their doctors." That's the deadly power of mass
advertising for drugs.
- Some ads are simply frauds, including one that Pfizer
ran on TV until 2006, hailing the prowess of the company's
cholesterol-lowering drug, Lipitor. The star of the spot was Robert
Jarvik, who was described as the well-known "physician" who was the
"inventor" of the artificial heart. In a picturesque outdoorsy setting,
he was shown vigorously rowing a boat across a lake -- visual "proof" that
his own heart was in robust condition thanks to his use of Lipitor. His
tagline was: "You don't have to be a doctor to appreciate that." Good,
because he doesn't practice medicine, and while he worked on the
artificial heart, he did not invent it. Oh, he also wasn't rowing the
boat -- a double played that role. Embarrassed, Pfizer had to yank the
ad -- but it continues to merchandize Lipitor with some $250 million a
year in commercials, generating about $11 billion a year in sales, more
than any other pharmaceutical in history.
- Bear in mind that these pitches are being made to consumers who cannot just go purchase the product--only licensed medical professionals can diagnose and prescribe. But, again, the promotions work, as an industry spokesman happily affirmed: "There's a strong correlation between the amount of money pharmaceutical companies spend on DTC advertising and what drug patients are most often requesting from physicians." He also noted that the trumpeting of brand-name pills "is definitely driving patients to the doctor's office." No surprise, then, that prescription drug use has soared in the past decade, during which spending (by consumers, private health plans, and governments) more than doubled. A 2010 survey by the National Center for Health Statistics not only found that about 35 percent of Americans over 60 take five or more prescription medicines a day (more than twice the intake in 1999), but even 22 percent of children under age 12 are on at least one Rx regimen. "People may be taking too many drugs," deadpanned the NCHS leader. And in recent years, a whole new market has opened up for DTC hucksters: Medical devices. In 2007, Johnson & Johnson launched the first mass-audience TV commercials for highly specialized, complex therapeutic devices. This is beyond odd; it is dangerous. Only expert practitioners have the knowledge and experience to judge whether one brand-name medical gizmo is superior to another. Yet, here was J&J doing a pitch to us clueless consumers for "Cypher," a drug-coated coronary stent for opening closed arteries. I'm all for consumers getting more say in health care, but--come on!--how would I know enough about the efficacy of various stents to instruct my doctor to "Make mine Cyphers"?
In addition to getting you and me to push particular products on our doctors, the drug and device industry runs a massive, sophisticated, and relentless "Direct-to-Doctor" sales program that skates on the thinnest ethical ice and frequently plunges all the way into illegality. While these efforts, costing more than $6 billion a year, occasionally pretend to be "educational," they are in fact an elaborate exercise in medical flimflammery -- nothing but a door-to-door ploy by each of the major makers to hoodwink your doctor into prescribing their brand-name pill, rather than a competitor's brand or a generic.